Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ellis Mez

Internal Medicine Eldersburg, MD Medical Doctor

NPI 1023029956 CMS profile 273349

1645 Liberty Rd, Suite 204, Eldersburg, MD 21784

Open in the dashboard

General payments

$4,599

244 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ellis Mez of Eldersburg, MD is reported in the CMS Open Payments database as having received $4,599 across 244 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $929 46
2024 General $921 44
2023 General $712 37
2022 General $694 35
2021 General $659 39
2020 General $422 26
2019 General $261 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ellis Mez
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ellis Mez were reported at $929. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ellis Mez Internal Medicine median Middle half National median
2019 $261 $159 $48–$570 $163
2020 $422 $119 $33–$402 $114
2021 $659 $135 $37–$521 $132
2022 $694 $141 $42–$496 $149
2023 $712 $149 $45–$519 $160
2024 $921 $154 $47–$537 $164
2025 $929 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $859 47 payments
  2. AbbVie, Inc. $478 22 payments
  3. Amgen Inc. $407 23 payments
  4. AstraZeneca Pharmaceuticals LP $379 19 payments
  5. Lilly USA, LLC $370 19 payments
  6. Pfizer Inc. $364 21 payments
  7. GlaxoSmithKline, LLC. $333 18 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $214 11 payments
  9. Merck Sharp & Dohme Corporation $162 9 payments
  10. Amarin Pharma Inc. $118 6 payments
  11. Other $916 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,599 244 payments
Products named General payments · program years 2019–2025
  1. Ozempic $623 36 payments
  2. RYBELSUS $561 32 payments
  3. UBRELVY $326 15 payments
  4. Otezla $255 14 payments
  5. Repatha $246 14 payments
  6. QULIPTA $218 10 payments
  7. FARXIGA $202 11 payments
  8. NURTEC ODT $155 9 payments
  9. EMGALITY $146 8 payments
  10. JARDIANCE $137 7 payments
  11. Other $3,990 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

2,076

Median for Internal Medicine: 777

Drug cost

$257,421

Median for Internal Medicine: $73,373

Branded share of claims

20.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 59 $56,378
Rybelsus Semaglutide Brand 25 $42,586
Eliquis Apixaban Brand 37 $40,850
Jardiance Empagliflozin Brand 30 $37,136
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $21,061
Xarelto Rivaroxaban Brand 17 $19,987
Linzess Linaclotide Brand 12 $6,234
Breo Ellipta Fluticasone/Vilanterol Brand 11 $4,765
Atorvastatin Calcium Generic 244 $3,722
Irbesartan Generic 89 $2,700

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$76,122

Of which drugs: $21,814

Medicare patients

192

Average age 78

Services billed

1,555

89 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 30%
Ischemic heart disease 26%
Chronic kidney disease 21%
Atrial fibrillation 16%
Cancer 14%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 89 89 $7,190
Pcv20 vaccine im 90677 Office 24 24 $6,672
Sarscv2 vac 30mcg trs-suc im 91320 Office 42 42 $6,417

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $121
$121 59 —
RYBELSUS
  • Novo Nordisk Inc $80
$80 25 —
Otezla
  • Amgen Inc. $72
$72 — —
Repatha
  • Amgen Inc. $72
$72 — —
ZEPBOUND
  • Lilly USA, LLC $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record